Hoth Therapeutics (NASDAQ:HOTH) Raised to “Sell” at Wall Street Zen

Hoth Therapeutics (NASDAQ:HOTH) was upgraded by Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

A number of other brokerages also recently weighed in on HOTH. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Hoth Therapeutics in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $5.00.

Hoth Therapeutics Price Performance

Shares of NASDAQ HOTH opened at $0.99 on Friday. Hoth Therapeutics has a 1 year low of $0.66 and a 1 year high of $2.12. The stock has a market cap of $15.40 million, a P/E ratio of -0.94 and a beta of 0.50. The firm has a 50-day moving average of $1.00 and a 200 day moving average of $1.23.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HOTH. Lido Advisors LLC purchased a new position in shares of Hoth Therapeutics during the 3rd quarter worth $32,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Hoth Therapeutics in the 3rd quarter worth $51,000. Virtu Financial LLC purchased a new stake in shares of Hoth Therapeutics in the 3rd quarter worth $184,000. Geode Capital Management LLC raised its holdings in Hoth Therapeutics by 8.0% in the 2nd quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock worth $143,000 after purchasing an additional 9,071 shares during the period. Finally, Citadel Advisors LLC bought a new position in Hoth Therapeutics in the 3rd quarter worth $232,000. 7.08% of the stock is currently owned by institutional investors.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.